

David M Goldenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11904539/publications.pdf>

Version: 2024-02-01

457
papers

24,417
citations

6233

80
h-index

14702

127
g-index

462
all docs

462
docs citations

462
times ranked

13210
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Peptide Camptothecin Drug-linkers for Potent ADCs Letter. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 237-237.	1.9	1
2	Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 954-955.	0.5	11
3	Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1221-1227.	2.8	12
4	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	13.9	601
5	Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. <i>Biomedicines</i> , 2020, 8, 548.	1.4	8
6	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1205-1211.	2.8	22
7	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	1.4	57
8	Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer. <i>Oncotarget</i> , 2020, 11, 3849-3862.	0.8	22
9	Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. <i>MAbs</i> , 2019, 11, 987-995.	2.6	74
10	Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches. <i>Frontiers in Medicine</i> , 2019, 6, 124.	1.2	20
11	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	13.9	542
12	A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer. <i>EJNMMI Research</i> , 2019, 9, 86.	1.1	4
13	Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models. <i>EJNMMI Research</i> , 2019, 9, 108.	1.1	7
14	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 763-773.	2.9	49
15	Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). <i>Molecular Cancer Therapeutics</i> , 2018, 17, 196-203.	1.9	24
16	IMMU-140, a Novel SN-38 Antibody Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 150-160.	1.9	20
17	The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. <i>Oncotarget</i> , 2018, 9, 28989-29006.	0.8	169
18	Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2018, 25, 37-40.	0.3	15

#	ARTICLE	IF	CITATIONS
19	Sensitivity of pretargeted immunoPET using ⁶⁸ Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with ¹⁸ F-FDG PET-CT. <i>Oncotarget</i> , 2018, 9, 27502-27513.	0.8	12
20	Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3405-3415.	3.2	92
21	¹²⁵ I- Versus ¹²⁵ I-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. <i>Journal of Nuclear Medicine</i> , 2017, 58, 926-933.	2.8	34
22	Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. <i>Journal of Nuclear Medicine</i> , 2017, 58, 706-710.	2.8	37
23	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	1.7	6
24	Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. <i>Cancer</i> , 2017, 123, 3843-3854.	2.0	145
25	Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰ Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e35-e45.	2.2	33
26	Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. <i>Cancer</i> , 2017, 123, 638-649.	2.0	30
27	Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. <i>Cancer Research</i> , 2017, 77, 5384-5394.	0.4	60
28	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-1-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. <i>Clinical Cancer Research</i> , 2017, 23, 5711-5719.	3.2	107
29	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	0.8	283
30	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. <i>Journal of Clinical Oncology</i> , 2017, 35, 2790-2797.	0.8	119
31	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3338-3346.	0.8	69
32	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 2017, 2141-2148.	0.8	6
33	Enhancing the antitumor potency of T cells redirected by bispecific antibodies. <i>Oncoscience</i> , 2017, 4, 120-121.	0.9	3
34	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. <i>Haematologica</i> , 2016, 101, 1327-1332.	1.7	9
35	Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and ⁶⁸ Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1505-1511.	2.8	61
36	Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1910-1919.	1.9	30

#	ARTICLE	IF	CITATIONS
37	Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opinion on Biological Therapy, 2016, 16, 883-893.	1.4	29
38	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*. Leukemia and Lymphoma, 2016, 57, 803-811.	0.6	12
39	Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e75-e79.	0.9	80
40	Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).. Journal of Clinical Oncology, 2016, 34, 8559-8559.	0.8	4
41	Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology, 2016, 34, 9011-9011.	0.8	4
42	The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology, 2015, 169, 701-710.	1.2	31
43	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatric Blood and Cancer, 2015, 62, 1171-1175.	0.8	89
44	Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*. Oncotarget, 2015, 6, 22496-22512.	0.8	303
45	Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients. Frontiers in Medicine, 2015, 2, 84.	1.2	29
46	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Molecular Imaging, 2015, 14, 7290.2015.00015.	0.7	37
47	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. MAbs, 2015, 7, 199-211.	2.6	17
48	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1079-1086.	2.5	59
49	Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research, 2015, 21, 5131-5138.	3.2	122
50	A pretargeting system for tumor PET imaging and radioimmunotherapy. Frontiers in Pharmacology, 2015, 6, 54.	1.6	41
51	Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjugate Chemistry, 2015, 26, 919-931.	1.8	184
52	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematology, the, 2015, 2, e108-e117.	2.2	36
53	Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts. Molecular Imaging and Biology, 2015, 17, 94-101.	1.3	17
54	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	1.3	10

#	ARTICLE	IF	CITATIONS
55	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 3870-3878.	3.2	223
56	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	1.7	26
57	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. <i>European Journal of Cancer</i> , 2015, 51, 1857-1864.	1.3	26
58	Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug. <i>Molecular Pharmaceutics</i> , 2015, 12, 1836-1847.	2.3	45
59	Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results. <i>Cancer Research</i> , 2015, 75, CT236-CT236.	0.4	4
60	Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552). <i>Cancer Research</i> , 2015, 75, P5-19-27-P5-19-27.	0.4	3
61	Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. <i>Oncotarget</i> , 2015, 6, 4274-4285.	0.8	19
62	Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results. <i>Cancer Research</i> , 2015, 75, P5-19-08-P5-19-08.	0.4	1
63	Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. <i>PLoS ONE</i> , 2014, 9, e98315.	1.1	24
64	In-Vivo Fusion of Human Cancer and Hamster Stromal Cells Permanently Transduces and Transcribes Human DNA. <i>PLoS ONE</i> , 2014, 9, e107927.	1.1	15
65	A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. <i>MAbs</i> , 2014, 6, 381-391.	2.6	34
66	CD74 interferes with the expression of fas receptor on the surface of lymphoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 80.	3.5	15
67	Al ¹⁸ F labeling of peptides and proteins. <i>Journal of Labelled Compounds and Radiopharmaceutics</i> , 2014, 57, 219-223.	0.5	44
68	Preclinical Comparison of Al ¹⁸ F- and ⁶⁸ Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2050-2056.	2.8	46
69	Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2 Bispecific Antibody Is Enhanced in Combination with Interferon- γ . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2341-2351.	1.9	19
70	Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 6216-6223.	0.4	25
71	Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. <i>Haematologica</i> , 2014, 99, 1738-1745.	1.7	25
72	Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris. <i>JAMA Dermatology</i> , 2014, 150, 1331.	2.0	52

#	ARTICLE	IF	CITATIONS
73	Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. <i>Molecular Cancer</i> , 2014, 13, 53.	7.9	22
74	Al18F Labeling of Affibody Molecules. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1043.1-1043.	2.8	9
75	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2—Anti-HSG Bispecific Antibody and a ¹⁷⁷ Lu-Labeled Peptide. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 323-329.	0.7	28
76	Differentiation of Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis by PAM4 Immunohistochemistry. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 220-228.	1.2	22
77	SPECT- and Fluorescence Image—Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen—Targeting Antibody. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1519-1524.	2.8	35
78	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1593-602.	3.3	33
79	¹⁸ F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1501-1510.	3.3	14
80	Radiopharmaceutical therapy in the era of precision medicine. <i>European Journal of Cancer</i> , 2014, 50, 2360-2363.	1.3	16
81	Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results. <i>Cancer Research</i> , 2014, 74, CT206-CT206.	0.4	5
82	Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies. <i>Cancer Research</i> , 2014, 74, CT211-CT211.	0.4	7
83	Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 3107-3107.	0.8	4
84	Radiofluorination using aluminum-fluoride (Al18F). <i>EJNMMI Research</i> , 2013, 3, 36.	1.1	98
85	Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. <i>BMC Cancer</i> , 2013, 13, 170.	1.1	27
86	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. <i>British Journal of Haematology</i> , 2013, 162, 693-701.	1.2	25
87	Prevention of Acute Graft-versus-Host Disease in a Xenogeneic SCID Mouse Model by the Humanized Anti-CD74 Antagonistic Antibody Milatuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 28-39.	2.0	15
88	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. <i>Blood</i> , 2013, 122, 3020-3029.	0.6	98
89	^B CR— ^A BL1 molecular remission after ⁹⁰ Y—epratuzumab tetraxetan radioimmunotherapy in ^{CD} 22 ⁺ ^P h ⁺ ^B — ^{ALL} : proof of principle. <i>European Journal of Haematology</i> , 2013, 91, 552-556.	1.1	19
90	Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. <i>Molecular Cancer</i> , 2013, 12, 143.	7.9	25

#	ARTICLE	IF	CITATIONS
91	Medullary Thyroid Carcinoma. , 2013, , 155-163.		0
92	Antibody-Targeted Therapeutic Radionuclides in the Management of Colorectal Cancer. , 2013, , 207-237.		2
93	Radioimmunotherapy of Pancreatic Adenocarcinoma. , 2013, , 239-255.		0
94	Pretargeting: Advancing the Delivery of Radionuclides. , 2013, , 369-381.		0
95	Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties. Bioconjugate Chemistry, 2013, 24, 63-71.	1.8	22
96	Imaging integrin $\alpha v \beta 3$ expression in tumors with an ^{18}F -labeled dimeric RGD peptide. Contrast Media and Molecular Imaging, 2013, 8, 238-245.	0.4	36
97	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1377-1383.	3.3	41
98	PAM4 enzyme immunoassay alone and in combination with CA 19 μ for the detection of pancreatic adenocarcinoma. Cancer, 2013, 119, 522-528.	2.0	38
99	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology, 2013, 52, 1313-1322.	0.9	115
100	Milatumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. Clinical Cancer Research, 2013, 19, 347-356.	3.2	34
101	Milatumab μ -SN-38 Conjugates for the Treatment of CD74+ Cancers. Molecular Cancer Therapeutics, 2013, 12, 968-978.	1.9	105
102	The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes. Antibodies, 2013, 2, 353-370.	1.2	4
103	Phase I, multicentre, dose μ escalation trial of monotherapy with milatumab (humanized) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Journal of Haematology, 2013, 163, 478-486.	1.2	89
104	^{18}F : A New Standard for Radiofluorination. Journal of Nuclear Medicine, 2013, 54, 1170.1-1170.	2.8	6
105	Monoclonal antibodies targeting CD20. MAbs, 2013, 5, 335-336.	2.6	3
106	Interferon- γ 1 Linked to a Stabilized Dimer of Fab Potently Enhances both Antitumor and Antiviral Activities in Targeted Cells. PLoS ONE, 2013, 8, e63940.	1.1	8
107	Preface: Special Issue on Tumor-Stromal Crosstalk in Oncogenesis. Critical Reviews in Oncogenesis, 2013, 18, v-vii.	0.2	0
108	Horizontal Transmission of Malignancy: In-Vivo Fusion of Human Lymphomas with Hamster Stroma Produces Tumors Retaining Human Genes and Lymphoid Pathology. PLoS ONE, 2013, 8, e55324.	1.1	18

#	ARTICLE	IF	CITATIONS
109	Medullary Thyroid Carcinoma. <i>Medical Radiology</i> , 2012, , 315-321.	0.0	0
110	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1185-1192.	2.8	74
111	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1926-1932.	2.8	12
112	Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time. <i>Journal of Clinical Oncology</i> , 2012, 30, 2165-2165.	0.8	8
113	Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. <i>Medical Radiology</i> , 2012, , 551-556.	0.0	1
114	Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. <i>Blood</i> , 2012, 119, 3767-3778.	0.6	43
115	A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1625-1632.	2.8	35
116	PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an ¹⁸ F-Labeled Bombesin Analog. <i>Journal of Nuclear Medicine</i> , 2012, 53, 947-952.	2.8	65
117	New Lyophilized Kit for Rapid Radiofluorination of Peptides. <i>Bioconjugate Chemistry</i> , 2012, 23, 538-547.	1.8	77
118	Epratuzumab- ¹²⁵ I-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 224-234.	1.9	62
119	Designing immunoconjugates for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 873-890.	1.4	45
120	Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies. <i>Medical Radiology</i> , 2012, , 607-615.	0.0	0
121	Antibodies for Nuclear Medicine Therapy. <i>Medical Radiology</i> , 2012, , 125-138.	0.0	0
122	The Dock-and-Lock Method Combines Recombinant Engineering with Site-Specific Covalent Conjugation To Generate Multifunctional Structures. <i>Bioconjugate Chemistry</i> , 2012, 23, 309-323.	1.8	43
123	Complex and defined biostructures with the dock-and-lock method. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 474-481.	4.0	15
124	The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. <i>Arthritis Research and Therapy</i> , 2012, 14, R54.	1.6	30
125	A Novel Class of Anti-HIV Agents with Multiple Copies of Enfuvirtide Enhances Inhibition of Viral Replication and Cellular Transmission In Vitro. <i>PLoS ONE</i> , 2012, 7, e41235.	1.1	15
126	Pretargeted Molecular Imaging and Radioimmunotherapy. <i>Theranostics</i> , 2012, 2, 523-540.	4.6	86

#	ARTICLE	IF	CITATIONS
127	Horizontal transmission of malignancy by cell-cell fusion. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, S133-S139.	1.4	29
128	Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 131, 49-58.	2.3	36
129	Using antibodies to target cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1173-1190.	1.4	19
130	Fractionated radioimmunotherapy with ⁹⁰ Y-ivabuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. <i>Cancer</i> , 2012, 118, 5497-5506.	2.0	79
131	Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC). <i>Tumor Biology</i> , 2012, 33, 601-606.	0.8	14
132	Pretargeting: taking an alternate route for localizing radionuclides. <i>Tumor Biology</i> , 2012, 33, 591-600.	0.8	28
133	Introduction to this special issue on tumor targeting. <i>Tumor Biology</i> , 2012, 33, 571-572.	0.8	0
134	The radiolabeling of proteins by the [18F]AlF method. <i>Applied Radiation and Isotopes</i> , 2012, 70, 200-204.	0.7	53
135	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. <i>EJNMMI Research</i> , 2012, 2, 5.	1.1	22
136	Optimized labeling of NOTA-conjugated octreotide with F-18. <i>Tumor Biology</i> , 2012, 33, 427-434.	0.8	72
137	Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines. <i>PLoS ONE</i> , 2012, 7, e44235.	1.1	8
138	In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67/68Ga)-labeled haptens by pretargeting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 141-50.	1.0	13
139	High-Yielding Aqueous ¹⁸ F-Labeling of Peptides via Al ¹⁸ F Chelation. <i>Bioconjugate Chemistry</i> , 2011, 22, 1793-1803.	1.8	137
140	Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced ⁶⁸ Ga. <i>Journal of Nuclear Medicine</i> , 2011, 52, 555-559.	2.8	22
141	Recent progress in cancer therapy with radiolabeled monoclonal antibodies. <i>Therapeutic Delivery</i> , 2011, 2, 675-679.	1.2	5
142	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. <i>Blood</i> , 2011, 117, 4530-4541.	0.6	75
143	Preclinical studies on targeted delivery of multiple IFN γ 2b to HLA-DR in diverse hematologic cancers. <i>Blood</i> , 2011, 118, 1877-1884.	0.6	33
144	FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. <i>Blood</i> , 2011, 118, 6893-6903.	0.6	46

#	ARTICLE	IF	CITATIONS
145	Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2153-2164.	3.3	25
146	A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines. <i>Biotechnology Progress</i> , 2011, 27, 766-775.	1.3	11
147	Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1601-1607.	2.8	29
148	Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1072-1081.	1.9	44
149	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 567-573.	1.7	47
150	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2011, 17, 4091-4100.	3.2	60
151	Cancer radioimmunotherapy. <i>Immunotherapy</i> , 2011, 3, 349-370.	1.0	108
152	Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys. <i>Clinical Cancer Research</i> , 2011, 17, 3157-3169.	3.2	213
153	Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 273-284.	0.6	16
154	Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. <i>Blood</i> , 2010, 115, 5180-5190.	0.6	43
155	Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. <i>Blood</i> , 2010, 116, 2554-2558.	0.6	40
156	Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. <i>Blood</i> , 2010, 116, 3258-3267.	0.6	36
157	Introduction to the supplement, "Cancer Therapy with Antibodies and Immunoconjugates". <i>Cancer</i> , 2010, 116, 1011-1012.	2.0	0
158	Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. <i>Cancer</i> , 2010, 116, 1093-1100.	2.0	33
159	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-ethylenetriaminepentaacetic acid F(ab') ₂ antibody. <i>Cancer</i> , 2010, 116, 1111-1117.	2.0	20
160	Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. <i>Cancer</i> , 2010, 116, 1118-1125.	2.0	19
161	Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. <i>Cancer</i> , 2010, 116, 1134-1145.	2.0	21
162	New Antibody Conjugates in Cancer Therapy. <i>Scientific World Journal</i> , The, 2010, 10, 2070-2089.	0.8	42

#	ARTICLE	IF	CITATIONS
163	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	0.8	106
164	Detection of Early-Stage Pancreatic Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2786-2794.	1.1	45
165	Pretargeted Immuno- α -Positron Emission Tomography Imaging of Carcinoembryonic Antigen- α -Expressing Tumors with a Bispecific Antibody and a ^{68}Ga - and ^{18}F -Labeled Hapten Peptide in Mice with Human Tumor Xenografts. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1019-1027.	1.9	85
166	Pretargeted ^{177}Lu Radioimmunotherapy of Carcinoembryonic Antigen- α -Expressing Human Colonic Tumors in Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1780-1787.	2.8	49
167	Immuno-PET Quantitation of de2-7 Epidermal Growth Factor Receptor Expression in Glioma Using ^{124}I -IMP-R4 α -Labeled Antibody ch806. <i>Journal of Nuclear Medicine</i> , 2010, 51, 967-972.	2.8	26
168	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010, 51, 747-755.	0.6	52
169	Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti- α -Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2276-2286.	1.9	48
170	TAp63 Regulates VLA-4 Expression and Chronic Lymphocytic Leukemia Cell Migration to the Bone Marrow in a CD74-Dependent Manner. <i>Journal of Immunology</i> , 2010, 184, 4761-4769.	0.4	53
171	A Novel Facile Method of Labeling Octreotide with ^{18}F -Fluorine. <i>Journal of Nuclear Medicine</i> , 2010, 51, 454-461.	2.8	193
172	Radioactive Antibodies: A Historical Review of Selective Targeting and Treatment of Cancer. <i>Hospital Practice (1995)</i> , 2010, 38, 82-93.	0.5	9
173	A Bispecific Antibody-IFN γ 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. <i>Cancer Research</i> , 2010, 70, 7600-7609.	0.4	41
174	Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 1-12.	0.7	19
175	Improved ^{18}F Labeling of Peptides with a Fluoride-Aluminum-Chelate Complex. <i>Bioconjugate Chemistry</i> , 2010, 21, 1331-1340.	1.8	178
176	Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 190-203.	2.5	70
177	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R204.	1.6	86
178	New agents and approaches to the treatment of B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 569-583.	1.0	2
179	Immunoconjugate Anticancer Therapeutics. , 2010, , 371-392.		1
180	Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 4, 1-12.	0.5	15

#	ARTICLE	IF	CITATIONS
181	Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. <i>Clinical Cancer Research</i> , 2009, 15, 2808-2817.	3.2	54
182	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. <i>Journal of Clinical Oncology</i> , 2009, 27, 3346-3353.	0.8	154
183	Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 185-193.	0.7	9
184	CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates. <i>Clinical Cancer Research</i> , 2009, 15, 6052-6061.	3.2	105
185	Advances and challenges in developing cytokine fusion proteins as improved therapeutics. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 181-194.	2.5	13
186	Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. <i>Molecular Cancer Research</i> , 2009, 7, 890-896.	1.5	54
187	A Novel Method of ¹⁸ F Radiolabeling for PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 991-998.	2.8	349
188	Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10 ⁹⁰ Y-IMP-288 Alone and Combined with Gemcitabine. <i>Journal of Nuclear Medicine</i> , 2009, 50, 2008-2016.	2.8	50
189	A New Method to Produce MonoPEGylated Dimeric Cytokines Shown with Human Interferon- β . <i>Bioconjugate Chemistry</i> , 2009, 20, 1899-1907.	1.8	19
190	Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 444-453.	2.8	57
191	A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. <i>Blood</i> , 2009, 113, 3891-3895.	0.6	62
192	Novel strategies for improved cancer vaccines. <i>Expert Review of Vaccines</i> , 2009, 8, 567-576.	2.0	19
193	Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. <i>Blood</i> , 2009, 113, 1062-1070.	0.6	115
194	Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. <i>Blood</i> , 2009, 113, 6161-6171.	0.6	68
195	Some like it hot: lymphoma radioimmunotherapy. <i>Blood</i> , 2009, 113, 4823-4824.	0.6	2
196	CD20-targeted tetrameric interferon- β , a novel and potent immunocytokine for the therapy of B-cell lymphomas. <i>Blood</i> , 2009, 114, 3864-3871.	0.6	59
197	Therapy of human carcinoma xenografts with antibodies to EGFR and HER-2 conjugated to radionuclides emitting low-energy electrons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1249-1258.	3.3	10
198	Durable complete responses from therapy with combined epratuzumab and rituximab. <i>Cancer</i> , 2008, 113, 2714-2723.	2.0	102

#	ARTICLE	IF	CITATIONS
199	Use of antibodies and immunoconjugates for the therapy of more accessible cancers. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 1407-1420.	6.6	54
200	Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6916-6926.	2.9	115
201	Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab). <i>Clinical Cancer Research</i> , 2008, 14, 6154-6160.	3.2	45
202	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3756-3762.	0.8	211
203	A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma. <i>Cancer Research</i> , 2008, 68, 4819-4826.	0.4	69
204	Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting. <i>Journal of Nuclear Medicine</i> , 2008, 49, 158-163.	2.8	134
205	Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody. <i>Cancer Research</i> , 2008, 68, 5282-5290.	0.4	71
206	Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics. <i>Cancer Research</i> , 2008, 68, 8384-8392.	0.4	59
207	Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model. <i>Radiology</i> , 2008, 246, 497-507.	3.6	55
208	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. <i>Haematologica</i> , 2008, 93, 390-397.	1.7	45
209	Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. <i>Blood</i> , 2008, 111, 2211-2219.	0.6	52
210	Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types. <i>PPAR Research</i> , 2008, 2008, 1-7.	1.1	60
211	Novel radioimmunopharmaceuticals for cancer imaging and therapy. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 1302-16.	2.3	15
212	CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms. <i>Clinical Cancer Research</i> , 2007, 13, 5556s-5563s.	3.2	188
213	IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 13408-13413.	3.3	162
214	A Divalent Hapten-Peptide Induces Apoptosis in Human Non-Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 and Anti-Hapten Bispecific Antibodies. <i>Clinical Cancer Research</i> , 2007, 13, 5564s-5571s.	3.2	2
215	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4590-4597.	1.8	89
216	The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retained Bioactivity. <i>Clinical Cancer Research</i> , 2007, 13, 5586s-5591s.	3.2	68

#	ARTICLE	IF	CITATIONS
217	Bispecific Antibody Pretargeting of Radionuclides for Immuno- ^{99m} Tc Single-Photon Emission Computed Tomography and Immuno- ^{18F} FDG Positron Emission Tomography Molecular Imaging: An Update. <i>Clinical Cancer Research</i> , 2007, 13, 5577s-5585s.	3.2	36
218	Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 524-531.	1.9	66
219	PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7380-7387.	3.2	85
220	Cancer imaging and therapy with bispecific antibody pretargeting. <i>Update on Cancer Therapeutics</i> , 2007, 2, 19-31.	0.9	82
221	Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. <i>Molecular Immunology</i> , 2007, 44, 1331-1341.	1.0	176
222	Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. <i>BMC Cancer</i> , 2007, 7, 2.	1.1	192
223	Update of Carcinoembryonic Antigen Radioimmunotherapy with ¹³¹ I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group. <i>Annals of Surgical Oncology</i> , 2007, 14, 2577-2590.	0.7	74
224	Methods and goals for the use of in vitro and in vivo chemosensitivity testing. <i>Molecular Biotechnology</i> , 2007, 35, 185-197.	1.3	60
225	Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2007, 110, 3419-3419.	0.6	1
226	Targeting CD22 as a strategy for treating systemic autoimmune diseases. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 953-9.	0.9	28
227	Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. <i>Arthritis Research and Therapy</i> , 2006, 8, R129.	1.6	212
228	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R74.	1.6	267
229	Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. <i>Blood</i> , 2006, 108, 2736-2744.	0.6	50
230	Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. <i>Aids</i> , 2006, 20, 1911-1915.	1.0	16
231	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 47-55.	2.0	8
232	Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. <i>Ca-A Cancer Journal for Clinicians</i> , 2006, 56, 226-243.	157.7	207
233	B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: Comment on the editorial by St.Clair and Tedder. <i>Arthritis and Rheumatism</i> , 2006, 54, 2344-2344.	6.7	4
234	Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting. <i>Cancer Investigation</i> , 2006, 24, 82-97.	0.6	31

#	ARTICLE	IF	CITATIONS
235	Sphingolipid targets in cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 200-208.	1.9	125
236	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti- α -Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 1705-1711.	0.8	231
237	New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. <i>Journal of Clinical Oncology</i> , 2006, 24, 252-258.	0.8	126
238	Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 5587-5595.	3.2	36
239	Epratuzumab in the therapy of oncological and immunological diseases. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1341-1353.	1.1	54
240	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3880-3886.	0.8	148
241	Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 823-834.	0.8	327
242	Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 6841-6846.	3.3	196
243	Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity. <i>Blood</i> , 2006, 108, 2495-2495.	0.6	2
244	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. <i>Blood</i> , 2006, 108, 2719-2719.	0.6	7
245	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and ^{131}I -labeled bivalent hapten in a phase I optimization clinical trial. <i>Journal of Nuclear Medicine</i> , 2006, 47, 247-55.	2.8	88
246	Bispecific antibody pretargeting PET (immunoPET) with an ^{124}I -labeled hapten-peptide. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1678-88.	2.8	81
247	Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. <i>Blood</i> , 2005, 106, 4308-4314.	0.6	53
248	Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. <i>Nature Medicine</i> , 2005, 11, 1250-1255.	15.2	144
249	Comparison of IgG and F(ab α) 2 fragments of bispecific anti-RCC α -anti-DTln-1 antibody for pretargeting purposes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1089-1095.	3.3	9
250	Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 901-909.	3.3	18
251	Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 315-327.	2.0	48
252	Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With ^{131}I -Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 6763-6770.	0.8	126

#	ARTICLE	IF	CITATIONS
253	Inhibition of Adhesion, Invasion, and Metastasis by Antibodies Targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). <i>Cancer Research</i> , 2005, 65, 8809-8817.	0.4	184
254	Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft. <i>Clinical Cancer Research</i> , 2005, 11, 7879-7885.	3.2	58
255	Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 375-391.	0.8	35
256	Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2005, 11, 2727-2734.	3.2	19
257	Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 47-62.	1.3	32
258	Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. <i>Clinical Cancer Research</i> , 2005, 11, 7109s-7121s.	3.2	111
259	Anti-CD74 Antibody-Doxorubicin Conjugate, IMMU-110, in a Human Multiple Myeloma Xenograft and in Monkeys. <i>Clinical Cancer Research</i> , 2005, 11, 5257-5264.	3.2	162
260	Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells. <i>Clinical Cancer Research</i> , 2005, 11, 7122s-7129s.	3.2	46
261	Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab. <i>Clinical Cancer Research</i> , 2005, 11, 5215-5222.	3.2	109
262	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5044-5051.	0.8	164
263	Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen - Anti-Indium-Labeled Diethylenetriaminepentaacetic Acid Antibody. <i>Clinical Cancer Research</i> , 2005, 11, 7130s-7136s.	3.2	15
264	Development of humanized antibodies as cancer therapeutics. <i>Methods</i> , 2005, 36, 84-95.	1.9	46
265	¹⁷⁷ Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. <i>Nuclear Medicine and Biology</i> , 2005, 32, 269-278.	0.3	40
266	Deferoxamine as a chelator for ⁶⁷ Ga in the preparation of antibody conjugates. <i>Nuclear Medicine and Biology</i> , 2005, 32, 513-519.	0.3	30
267	Perspectives on cancer therapy with radiolabeled monoclonal antibodies. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 115S-27S.	2.8	48
268	Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. <i>Clinical Cancer Research</i> , 2005, 11, 777-86.	3.2	22
269	A phase I trial combining high-dose ⁹⁰ Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2005, 46, 620-33.	2.8	42
270	Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 8405-8410.	0.4	62

#	ARTICLE	IF	CITATIONS
271	Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 5327-5334.	3.2	221
272	CD74 Is Expressed by Multiple Myeloma and Is a Promising Target for Therapy. <i>Clinical Cancer Research</i> , 2004, 10, 6606-6611.	3.2	140
273	Improved Targeting of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3552-3561.	3.2	29
274	Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 2868-2878.	3.2	168
275	Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel. <i>Breast Cancer Research and Treatment</i> , 2004, 84, 173-182.	1.1	44
276	An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. <i>International Journal of Cancer</i> , 2004, 108, 293-300.	2.3	15
277	Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agent. <i>Journal of Pediatric Surgery</i> , 2004, 39, 1338-1344.	0.8	12
278	Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. <i>Blood</i> , 2004, 104, 3705-3711.	0.6	126
279	Construction and Characterization of a Novel Ribonuclease Immunotoxin Consisting of Two Ranpirnase (Rap) Molecules Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody. <i>Blood</i> , 2004, 104, 3289-3289.	0.6	1
280	Reagents and methods for PET using bispecific antibody pretargeting and ⁶⁸ Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. <i>Journal of Nuclear Medicine</i> , 2004, 45, 30-9.	2.8	43
281	Biodistribution and therapeutic efficacy of (¹²⁵ I)-, (¹⁸⁶ Re)-, (⁸⁸ Y)-, or (¹⁷⁷ Lu)-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1224-32.	2.8	53
282	A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1559-64.	1.9	22
283	Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 777-780.	3.3	39
284	Advancing role of radiolabeled antibodies in the therapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 281-296.	2.0	92
285	CD22-directed monoclonal antibody therapy for lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 457-464.	0.8	27
286	Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: Potential relationship to post-therapy tumor angiogenesis and recurrence. <i>International Journal of Cancer</i> , 2003, 105, 158-164.	2.3	54
287	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. <i>International Journal of Cancer</i> , 2003, 106, 965-972.	2.3	34
288	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90 Labeled Anti-CD22 Monoclonal Antibody. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 56-59.	2.1	11

#	ARTICLE	IF	CITATIONS
289	Experimental therapy of disseminated B-Cell lymphoma xenografts with ²¹³ Bi-labeled anti-CD74. <i>Nuclear Medicine and Biology</i> , 2003, 30, 715-723.	0.3	18
290	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3051-3059.	0.8	245
291	Biodistribution of ¹³¹ I-, ¹⁸⁶ Re-, ¹⁷⁷ Lu-, and ⁸⁸ Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 525-533.	0.7	25
292	Tumor pO ₂ Assessments in Human Xenograft Tumors Measured by EPR Oximetry: Location of Paramagnetic Materials. <i>Advances in Experimental Medicine and Biology</i> , 2003, 530, 205-214.	0.8	0
293	Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. <i>Journal of Nuclear Medicine</i> , 2003, 44, 67-76.	2.8	35
294	⁹⁰ Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. <i>Journal of Nuclear Medicine</i> , 2003, 44, 77-84.	2.8	54
295	Improved iodine radiolabels for monoclonal antibody therapy. <i>Cancer Research</i> , 2003, 63, 111-8.	0.4	49
296	A universal pretargeting system for cancer detection and therapy using bispecific antibody. <i>Cancer Research</i> , 2003, 63, 354-63.	0.4	75
297	Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. <i>Clinical Cancer Research</i> , 2003, 9, 3886S-96S.	3.2	30
298	Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. <i>Clinical Cancer Research</i> , 2003, 9, 3897S-913S.	3.2	35
299	Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. <i>Clinical Cancer Research</i> , 2003, 9, 3973S-81S.	3.2	37
300	Epratuzumab: targeting B-cell malignancies through CD22. <i>Clinical Cancer Research</i> , 2003, 9, 3991S-4S.	3.2	34
301	Radioimmunotherapy of non-Hodgkin's lymphoma with ⁹⁰ Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. <i>Journal of Nuclear Medicine</i> , 2003, 44, 2000-18.	2.8	62
302	Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. <i>Clinical Cancer Research</i> , 2003, 9, 6567-71.	3.2	61
303	Specifically Targeting the CD22 Receptor of Human B-cell Lymphomas with RNA Damaging Agents: A New Generation of Therapeutics. <i>Leukemia and Lymphoma</i> , 2002, 43, 953-959.	0.6	35
304	Use of Galactosylated-Streptavidin as a Clearing Agent with ¹¹¹ In-Labeled, Biotinylated Antibodies to Enhance Tumor/Non-Tumor Localization Ratios. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 307-316.	0.7	7
305	Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. <i>Cancer</i> , 2002, 94, 51-61.	2.0	30
306	Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. <i>Cancer</i> , 2002, 94, 1373-1381.	2.0	94

#	ARTICLE	IF	CITATIONS
307	Phase I Radioimmunotherapy Trial with Iodine-131 ¹²⁵ I Labeled Humanized MN-14 Anti ¹²⁵ I Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2002, 2, 31-42.	1.0	49
308	Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. <i>International Journal of Oncology</i> , 2002, 20, 379-84.	1.4	9
309	Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. <i>Clinical Cancer Research</i> , 2002, 8, 1213-22.	3.2	19
310	Targeted therapy of cancer with radiolabeled antibodies. <i>Journal of Nuclear Medicine</i> , 2002, 43, 693-713.	2.8	197
311	Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 553-63.	1.9	96
312	Potent and specific antitumor effects of an anti-CD22 ¹²⁵ I targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. <i>Blood</i> , 2001, 97, 528-535.	0.6	109
313	Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 173-180.	2.0	10
314	The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 195-201.	2.0	85
315	Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 147-154.	2.0	33
316	Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 79-86.	2.0	17
317	Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. <i>International Journal of Cancer</i> , 2001, 94, 564-571.	2.3	18
318	Unique molecular markers in human endometriosis: implications for diagnosis and therapy. <i>Expert Reviews in Molecular Medicine</i> , 2001, 3, 1-12.	1.6	4
319	Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. <i>Cancer</i> , 2000, 88, 333-343.	2.0	34
320	Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy. , 2000, 86, 276-280.		45
321	Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process. , 2000, 69, 74-82.		42
322	Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. <i>Cancer</i> , 2000, 89, 104-115.	2.0	14
323	Advances in the use of monoclonal antibodies in cancer radiotherapy. <i>Pharmaceutical Science & Technology Today</i> , 2000, 3, 90-98.	0.7	13
324	Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?11Dr Goldenberg is a member of the board of Immunomedics and a shareholder. Immunomedics markets CEA-Scan (arcitumomab).. <i>Journal of the American College of Surgeons</i> , 2000, 191, 511-518.	0.2	28

#	ARTICLE	IF	CITATIONS
325	CEA Immunoscintigraphy Detects Resectable Rectal Cancer Recurrence and Improves Survival. <i>Coloproctology</i> , 2000, 22, 23-28.	0.3	1
326	Sphingomyelin Potentiates Chemotherapy of Human Cancer Xenografts. <i>Biochemical and Biophysical Research Communications</i> , 2000, 268, 603-606.	1.0	27
327	Degranulating Eosinophils in Human Endometriosis. <i>American Journal of Pathology</i> , 2000, 156, 1581-1588.	1.9	51
328	Co-Secretion of Two Distinct Kappa Light Chains by the Mu-9 Hybridoma. <i>Hybridoma</i> , 1999, 18, 325-333.	0.9	4
329	Phase I/II trial of ¹³¹ I-MN-14 F(ab) ₂ anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. , 1999, 85, 1828-1842.		73
330	Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. , 1999, 81, 985-992.		47
331	Carcinoembryonic Antigen as a Target for Radioimmunotherapy of Human Medullary Thyroid Carcinoma: Antibody Processing, Targeting, and Experimental Therapy with ¹³¹ I and ⁹⁰ Y Labeled MAbs. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 1999, 14, 37-47.	0.7	19
332	Rapid diagnostic imaging of acute, nonclassic appendicitis by leukoscintigraphy with sulesomab, a technetium ^{99m} Tc-labeled antigranulocyte antibody Fab ² fragment. <i>Surgery</i> , 1999, 125, 288-296.	1.0	45
333	Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing D-Amino Acids. <i>Bioconjugate Chemistry</i> , 1999, 10, 231-240.	1.8	33
334	Breast cancer imaging with radiolabeled antibodies. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 41-48.	2.5	42
335	Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. <i>Journal of Immunological Methods</i> , 1998, 213, 131-144.	0.6	18
336	Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of ¹²⁵ I vs. ¹³¹ I-labeled CO17-1A in a human colorectal cancer model. , 1998, 76, 738-748.		45
337	Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. , 1998, 77, 787-795.		44
338	⁹⁰ Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: A Radiolabeling and Animal Biodistribution Study. <i>Bioconjugate Chemistry</i> , 1998, 9, 773-782.	1.8	26
339	Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men". <i>Hybridoma</i> , 1997, 16, 101-107.	0.9	33
340	Development of a Streptavidin ⁺ Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. <i>Reagent Development</i> . <i>Bioconjugate Chemistry</i> , 1997, 8, 585-594.	1.8	35
341	Development of a Streptavidin ⁺ Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. <i>Studies in a Human Colon Cancer Xenograft Model</i> . <i>Bioconjugate Chemistry</i> , 1997, 8, 595-604.	1.8	50
342	Changes in Tumor Vascular Permeability in Response to Experimental Radioimmunotherapy: A Comparative Study of 11 Xenografts. <i>Tumor Biology</i> , 1997, 18, 367-377.	0.8	16

#	ARTICLE	IF	CITATIONS
343	Prospects of Radioimmunotherapy in Epithelial Ovarian Cancer: Results with Iodine-131-Labeled Murine and Humanized MN-14 Anti-carcinoembryonic Antigen Monoclonal Antibodies. <i>Gynecologic Oncology</i> , 1997, 67, 259-271.	0.6	41
344	Perspectives on oncologic imaging with radiolabeled antibodies. <i>Cancer</i> , 1997, 80, 2431-2435.	2.0	35
345	Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. <i>Cancer</i> , 1997, 80, 2591-2610.	2.0	98
346	Defining the optimal spacing between repeat radioantibody doses in experimental models. <i>Cancer</i> , 1997, 80, 2624-2635.	2.0	4
347	Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. <i>Cancer</i> , 1997, 80, 2636-2641.	2.0	28
348	Can occult metastases be Treated by radioimmunotherapy?. <i>Cancer</i> , 1997, 80, 2656-2659.	2.0	10
349	Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). <i>Cancer</i> , 1997, 80, 2660-2666.	2.0	13
350	Chimerization of mu-9. <i>Cancer</i> , 1997, 80, 2667-2674.	2.0	7
351	Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies. <i>Cancer</i> , 1997, 80, 2749-2753.	2.0	7
352	Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice. , 1997, 70, 323-329.		4
353	The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody. , 1997, 71, 429-435.		22
354	Application of cytokine intervention for improved radio-antibody dose delivery. , 1997, 72, 166-173.		5
355	Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. , 1997, 72, 477-485.		45
356	Use of Carcinoembryonic Antigen Radioimmunodetection and Computed Tomography for Predicting the Resectability of Recurrent Colorectal Cancer. <i>Annals of Surgery</i> , 1997, 226, 621-631.	2.1	45
357	Thiolations, 99mTc Labelings, and Animal In Vivo Biodistributions of Divalent Monoclonal Antibody Fragments. <i>Bioconjugate Chemistry</i> , 1996, 7, 290-297.	1.8	5
358	Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. <i>Biochemical Journal</i> , 1996, 320, 293-300.	1.7	80
359	Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2. , 1996, 78, 157-168.		21
360	Rapid Imaging of Infections With a Monoclonal Antibody Fragment (LeukoScan). <i>Clinical Orthopaedics and Related Research</i> , 1996, 329, 263-272.	0.7	80

#	ARTICLE	IF	CITATIONS
361	Carcinoembryonic Antigen as a Target Cancer Antigen for Radiolabeled Antibodies: Prospects for Cancer Imaging and Therapy. <i>Tumor Biology</i> , 1995, 16, 62-73.	0.8	20
362	Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. <i>International Journal of Cancer</i> , 1995, 60, 534-538.	2.3	14
363	Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability. <i>International Journal of Cancer</i> , 1995, 61, 557-566.	2.3	26
364	The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7 ^{3G11} , is phosphorylated on serine 303. <i>International Journal of Cancer</i> , 1995, 62, 472-479.	2.3	74
365	Clinical Utility of Radioimmunoscintigraphy of Non-Hodgkin's Lymphoma with Radiolabelled LL2 Monoclonal Antibody., <i>Lymphoscana</i> , ϕ : Preliminary Results. <i>Tumori</i> , 1995, 81, 173-178.	0.6	5
366	Tumor targeting and pharmacokinetics of unmodified and modified F(ab) ₂ fragments of an anti-CEA murine monoclonal antibody (Immu-14). <i>Nuclear Medicine and Biology</i> , 1995, 22, 425-435.	0.3	4
367	Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. <i>Molecular Immunology</i> , 1995, 32, 1413-1427.	1.0	96
368	Internalization of an intact doxorubicin immunoconjugate. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 92-98.	2.0	42
369	Cytokine Intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF. <i>Cancer</i> , 1994, 73, 1083-1092.	2.0	13
370	Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. <i>Cancer</i> , 1994, 73, 761-768.	2.0	37
371	Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. <i>Cancer</i> , 1994, 73, 787-793.	2.0	82
372	Comparative biodistribution and radioimmunotherapy of monoclonal antibody rs7 and its f(ab ²) ₂ in nude mice bearing human tumor xenografts. <i>Cancer</i> , 1994, 73, 816-823.	2.0	16
373	Phase I clinical evaluation of a new murine monoclonal antibody (mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. <i>Cancer</i> , 1994, 73, 864-877.	2.0	20
374	Internalization and intracellular processing of an anti B-cell lymphoma monoclonal antibody, ll2. <i>International Journal of Cancer</i> , 1994, 56, 538-545.	2.3	70
375	Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotypic antibody. <i>International Journal of Cancer</i> , 1994, 56, 580-584.	2.3	23
376	Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7. <i>International Journal of Cancer</i> , 1994, 57, 98-102.	2.3	53
377	The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. <i>Seminars in Nuclear Medicine</i> , 1994, 24, 142-153.	2.5	127
378	Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen. <i>Gastroenterology</i> , 1994, 106, 1242-1250.	0.6	36

#	ARTICLE	IF	CITATIONS
379	Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. <i>Cancer</i> , 1993, 71, 2082-2096.	2.0	53
380	Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. <i>Cancer</i> , 1993, 71, 3478-3485.	2.0	68
381	Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. <i>International Journal of Cancer</i> , 1993, 55, 938-946.	2.3	75
382	Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. <i>Cancer Immunology, Immunotherapy</i> , 1993, 37, 293-298.	2.0	70
383	Monoclonal antibodies in cancer detection and therapy. <i>American Journal of Medicine</i> , 1993, 94, 297-312.	0.6	133
384	Microheterogeneity of a purified IgG1, due to asymmetric fab glycosylation. <i>Molecular Immunology</i> , 1992, 29, 751-758.	1.0	26
385	Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1992, 19, 87-99.	0.3	6
386	Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. <i>Bioconjugate Chemistry</i> , 1992, 3, 91-99.	1.8	67
387	Endobronchial Deposition of Radioactive Monoclonal Antibody in Patients with Inoperable Non-Small-Cell Carcinoma of the Lung. <i>Chest</i> , 1992, 102, 1633-1634.	0.4	0
388	Lymphoma imaging with a new technetium-99m labelled antibody, LL2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 394-401.	2.2	27
389	Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 127-134.	2.0	19
390	Haematological effects of radioimmunotherapy in cancer patients. <i>British Journal of Haematology</i> , 1992, 80, 69-76.	1.2	10
391	Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotypic antibody in tumor-bearing nude mice. <i>International Journal of Cancer</i> , 1992, 51, 266-273.	2.3	27
392	Physiological factors influencing radioantibody uptake: A study of four human colonic carcinomas. <i>International Journal of Cancer</i> , 1992, 51, 935-941.	2.3	14
393	Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice. <i>Bioconjugate Chemistry</i> , 1991, 2, 102-110.	1.8	52
394	Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies. <i>Chest</i> , 1991, 99, 1466-1476.	0.4	16
395	SPECT Anti-CEA Monoclonal Antibody Detection of Occult Colorectal Carcinoma Metastases. <i>Clinical Nuclear Medicine</i> , 1991, 16, 849-852.	0.7	16
396	Labeling of monoclonal antibody conjugates with ⁹⁰ Y. <i>International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes</i> , 1991, 42, 421-426.	0.5	3

#	ARTICLE	IF	CITATIONS
397	The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 351-358.	2.0	50
398	Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. <i>Cancer Immunology, Immunotherapy</i> , 1991, 32, 303-310.	2.0	18
399	Suppression of Tumor Vascular Activity by Radioantibody Therapy: Implications for Multiple Cycle Treatments. <i>Selective Cancer Therapeutics</i> , 1991, 7, 9-16.	0.5	11
400	Cancer Imaging and Therapy with Radiolabeled Antibodies. <i>Advances in Experimental Medicine and Biology</i> , 1991, 303, 107-117.	0.8	3
401	Current perspectives and challenges in the use of monoclonal antibodies as imaging and therapeutic agents. <i>Advanced Drug Delivery Reviews</i> , 1990, 4, 279-318.	6.6	18
402	Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice. <i>Cancer Immunology, Immunotherapy</i> , 1990, 31, 197-201.	2.0	8
403	Selection of a dtpa chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. <i>International Journal of Cancer</i> , 1990, 46, 79-85.	2.3	30
404	Baboon anti-idiotypic antibodies mimic a carcinoembryonic antigen epitope. <i>International Journal of Cancer</i> , 1990, 46, 310-314.	2.3	14
405	A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model. <i>International Journal of Cancer</i> , 1990, 46, 1101-1106.	2.3	16
406	Cancer Imaging with Radiolabeled Antibodies. <i>Frontiers of Radiation Therapy and Oncology</i> , 1990, 24, 90-95.	1.4	9
407	Clinical radioimmunodetection: The second decade. <i>Cancer Treatment and Research</i> , 1990, 51, 3-9.	0.2	1
408	Labeling of anti-tumor antibodies and antibody fragments with Tc-99m. <i>Cancer Treatment and Research</i> , 1990, 51, 233-244.	0.2	7
409	In-vivo antibody imaging for the detection of human tumors. <i>Cancer Treatment and Research</i> , 1990, 51, 273-292.	0.2	9
410	Anti-antibody enhancement of tumor imaging. <i>Cancer Treatment and Research</i> , 1990, 51, 433-455.	0.2	8
411	Experimental model systems for antibody targeting and radioimmunodetection. <i>Cancer Treatment and Research</i> , 1990, 51, 29-52.	0.2	4
412	Comparison of therapeutic efficacy and host toxicity of two different ¹³¹ I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. <i>International Journal of Cancer</i> , 1989, 44, 292-300.	2.3	41
413	Imaging of colorectal carcinoma with radiolabeled antibodies. <i>Seminars in Nuclear Medicine</i> , 1989, 19, 262-281.	2.5	66
414	Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. <i>Seminars in Nuclear Medicine</i> , 1989, 19, 332-339.	2.5	68

#	ARTICLE	IF	CITATIONS
415	Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. International Journal of Cancer, 1988, 41, 832-839.	2.3	32
416	Purification and Characterization of Carcinoembryonic Antigen from GW-39, a Xenografted Human Colonic Tumor System. Tumor Biology, 1988, 9, 212-220.	0.8	13
417	Representation of Epitopes on Colon-Specific Antigen-p Defined by Monoclonal Antibodies <xref ref-type="fn" rid="FN2">2</xref>. Journal of the National Cancer Institute, 1987, , .	3.0	1
418	Antibody protein dose and radioimmunodetection of gw-39 human colon tumor xenografts. International Journal of Cancer, 1987, 39, 611-617.	2.3	22
419	Current status of cancer imaging with radiolabeled antibodies. Journal of Cancer Research and Clinical Oncology, 1987, 113, 203-208.	1.2	41
420	Preliminary findings in the evaluation of hepatic malignancies by radioimmunodetection, X-ray computed tomography, and magnetic resonance imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 12, 429-435.	2.2	6
421	Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. Seminars in Nuclear Medicine, 1985, 15, 2-11.	2.5	39
422	Clinical Studies of Prostatic Cancer Imaging with Radiolabeled Antibodies Against Prostatic Acid Phosphatase. Urologic Clinics of North America, 1984, 11, 277-281.	0.8	14
423	Antimarker antibodies for the external imaging of gastrointestinal cancer. Cancer Treatment and Research, 1984, , 351-362.	0.2	2
424	Radioimmunodetection of Prostatic Cancer. JAMA - Journal of the American Medical Association, 1983, 250, 630.	3.8	39
425	Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. Gastroenterology, 1983, 84, 524-532.	0.6	106
426	Radioactive antibodies for cancer detection in vivo. Clinical Immunology Newsletter, 1982, 3, 61-64.	0.1	1
427	Colon-specific antigen-p (CSAp). I: Initial clinical evaluation as a marker for colorectal cancer. Cancer, 1982, 50, 919-926.	2.0	15
428	Colon-specific antigen-p (CSAp). II: Further characterization in colorectal and pancreatic cancer. Cancer, 1982, 50, 927-931.	2.0	10
429	Carcinoembryonic Antigen: Its Role as a Marker in the Management of Cancer. A National Institutes of Health Consensus Development Conference. Annals of Internal Medicine, 1981, 94, 407.	2.0	65
430	Immunoperoxidase Localization of Carcinoembryonic Antigen in Normal Human Intestinal Mucosa <xref ref-type="fn" rid="FN2">2</xref> <xref ref-type="fn" rid="FN3">3</xref>. Journal of the National Cancer Institute, 1981, , .	3.0	7
431	Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). International Journal of Cancer, 1981, 27, 101-105.	2.3	41
432	Radioimmunodetection of colorectal cancer. Cancer, 1980, 45, 1243-1247.	2.0	25

#	ARTICLE	IF	CITATIONS
433	Clinical studies on the radioimmuno-detection of tumors containing alpha-fetoprotein. <i>Cancer</i> , 1980, 45, 2500-2505.	2.0	122
434	Antigens Associated with Human Solid Tumors. , 1980, , 329-369.		9
435	Alteration in tryptic peptide patterns of ferritins purified from human colon carcinoma. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1979, 581, 193-197.	1.7	4
436	Introduction to the international conference on the clinical uses of carcinoembryonic antigen. <i>Cancer</i> , 1978, 42, 1397-1398.	2.0	12
437	Immunoperoxidase detection of carcinoembryonic antigen.An overview. <i>Cancer</i> , 1978, 42, 1540-1545.	2.0	29
438	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. <i>Cancer</i> , 1978, 42, 1546-1553.	2.0	143
439	Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning. <i>New England Journal of Medicine</i> , 1978, 298, 1384-1388.	13.9	714
440	Immunoperoxidase detection of carcinoembryonic antigen.An overview. <i>Cancer</i> , 1978, 42, 1540-1545.	2.0	19
441	Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. <i>Cancer</i> , 1978, 42, 1546-1553.	2.0	97
442	Karyology of a human colonic carcinoma (GW-39) serially xenografted in hamsters and in nude mice. <i>Cancer Letters</i> , 1977, 2, 195-200.	3.2	8
443	Characterization and localization of carcinoembryonic antigen in a squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1976, 4, 204-211.	0.6	21
444	Carcinoembryonic Antigen in Histopathology: Immunoperoxidase Staining of Conventional Tissue Sections2. <i>Journal of the National Cancer Institute</i> , 1976, 57, 11-22.	3.0	209
445	Oncogenesis by interspecific interaction of malignant murine and non-malignant hamster cells in vitro. <i>International Journal of Cancer</i> , 1975, 15, 282-300.	2.3	7
446	Detection of carcinoembryonic antigen in tissue sections by immunoperoxidase. <i>Journal of Immunological Methods</i> , 1975, 8, 267-275.	0.6	51
447	Altered metabolism of carcinoembryonic antigen in hamsters bearing GW-39 tumours. <i>Nature</i> , 1974, 249, 837-838.	13.7	14
448	In vivo hybridisation of human tumour and normal hamster cells. <i>Nature</i> , 1974, 250, 649-651.	13.7	153
449	Synthesis of Carcinoembryonic Antigen in vitro. <i>Nature: New Biology</i> , 1972, 239, 189-190.	4.5	27
450	Stathmokinetic effect of colcemid on a presumptive human-hamster hybrid tumor, GW-478. <i>Experimental and Molecular Pathology</i> , 1971, 14, 134-137.	0.9	8

#	ARTICLE	IF	CITATIONS
451	Synergistic effects of X-rays and drugs on a human tumor xenograft, GW-39. European Journal of Cancer, 1970, 6, 73-80.	1.0	8
452	Identity and nature of isolated lymphoid tumors (so-called nodal hyperplasia, hamartoma, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 studies. Cancer, 1970, 25, 1286-1300.	2.0	64
453	Retention of Human Properties by a Xenografted Human Colonic Tumor, GW-77, Propagated in Unconditioned Hamsters. Experimental Biology and Medicine, 1970, 135, 657-659.	1.1	12
454	In vivo proliferation of heterotransplanted human cancer cells. European Journal of Cancer, 1967, 3, 315-319.	1.0	17
455	Chemotherapy of two morphologically similar human tumors growing in the cheek pouch of the golden hamster: H. Ad. No. 1 and GW-39. European Journal of Cancer, 1967, 3, 95-101.	1.0	21
456	GW-39: A NEW HUMAN TUMOR SERIALY TRANSPLANTABLE IN THE GOLDEN HAMSTER. Transplantation, 1966, 4, 760-763.	0.5	86
457	Radioactive antibodies: Selective targeting and treatment of cancer and other diseases. , 0, , 10-29.		4